Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid

Klaas P Koopmans; Adrienne H Brouwers; Marjolijn N De Hooge; Anouk N Van der Horst-Schrivers; Ido P Kema; Bruce H Wolffenbuttel; Elisabeth G De Vries; Pieter L Jager

Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid

J Nucl Med. 2005 Jul;46(7):1240-3.

Authors

Klaas P Koopmans¹, Adrienne H Brouwers, Marjolijn N De Hooge, Anouk N Van der Horst-Schrivers, Ido P Kema, Bruce H Wolffenbuttel, Elisabeth G De Vries, Pieter L Jager

Affiliation

¹ Department of Nuclear Medicine and PET Center, University Medical Center Groningen, Groningen, The Netherlands.

PMID: 16000294

Abstract

A carcinoid crisis is a severe complication of the carcinoid syndrome that can arise in patients with advanced metastatic neuroendocrine tumors. It can be initiated by stress, catecholamines, and tumor manipulation. In this article, we report a case in which an injection with the catecholamine tracer 6-18F-fluorodihydroxyphenylalanine, used for PET, induced a carcinoid crisis. Octreotide can be used for treatment and should be available. Tracer injection should be slow.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Dihydroxyphenylalanine / adverse effects*
Dihydroxyphenylalanine / analogs & derivatives*
Female
Gastrointestinal Neoplasms / chemically induced*
Gastrointestinal Neoplasms / diagnostic imaging
Gastrointestinal Neoplasms / drug therapy
Humans
Injections, Intravenous / adverse effects
Liver Neoplasms / diagnostic imaging*
Liver Neoplasms / secondary*
Malignant Carcinoid Syndrome / chemically induced*
Malignant Carcinoid Syndrome / diagnostic imaging
Malignant Carcinoid Syndrome / drug therapy
Middle Aged
Octreotide / therapeutic use
Radionuclide Imaging
Radiopharmaceuticals / adverse effects

Substances

Radiopharmaceuticals
fluorodopa F 18
Dihydroxyphenylalanine
Octreotide